Exploring ENS-002: A Microbiome-Based Therapy for Atopic Dermatitis
Time: 1:30 pm
day: Conference Day Two, Track Two, PM
Details:
- Targeting Staphylococcus aureus by using a combination of three microbial strains to restore balance to the skin microbiome without immune suppression
- Evaluating ENS-002’s safety and tolerability in Phase 1 clinical trials, with a focus on its impact on S. aureus abundance and atopic dermatitis symptoms
- Anticipating Phase 2 trial results, which will provide further insights into ENS-002’s efficacy and its potential to become a transformative treatment for atopic dermatitis
